ArticleJournal of translational medicine2026
Boosting the vascularization and regenerative capacity of nanofat by short-term ex vivo pretreatment with erythropoietin.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundErythropoietin (EPO) is a glycoprotein hormone that exerts pro-angiogenic and anti-inflammatory effects. The present study investigated whether this beneficial profile of action is suitable for improving the in vivo performance of nanofat, an emulsified fat derivative that is clinically used in plastic and reconstructive surgery.
resultsRepeated intravital fluorescent microscopic analyses showed that EPO-pretreated nanofat significantly accelerates and enhances the vascularization of the implants, as evidenced by an earlier onset of blood perfusion and an increased functional microvessel density when compared to controls. This was associated with a reduced inflammatory response to the implants, as indicated by lower numbers of adherent leukocytes in venules of the host tissue. Histological and immunohistochemical analyses further revealed an improved implant integration with an increased collagen I deposition and a higher density of nanofat-derived CD31⁺/green fluorescent protein (GFP
methodsNanofat was mechanically generated from subcutaneous adipose tissue of GFP
conclusionThese findings identify short-term pretreatment with EPO as an effective strategy to boost the vascularization and regenerative capacity of nanofat.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.